These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26390969)

  • 21. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
    Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
    Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
    Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. YAP activation is an early event and a potential therapeutic target in liver cancer development.
    Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
    J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Therapeutic Target for Prostate Cancer.
    Cancer Discov; 2016 Jun; 6(6):OF6. PubMed ID: 27091858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.
    Wang G; Lu X; Dey P; Deng P; Wu CC; Jiang S; Fang Z; Zhao K; Konaparthi R; Hua S; Zhang J; Li-Ning-Tapia EM; Kapoor A; Wu CJ; Patel NB; Guo Z; Ramamoorthy V; Tieu TN; Heffernan T; Zhao D; Shang X; Khadka S; Hou P; Hu B; Jin EJ; Yao W; Pan X; Ding Z; Shi Y; Li L; Chang Q; Troncoso P; Logothetis CJ; McArthur MJ; Chin L; Wang YA; DePinho RA
    Cancer Discov; 2016 Jan; 6(1):80-95. PubMed ID: 26701088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.
    Ashikari D; Takayama K; Tanaka T; Suzuki Y; Obinata D; Fujimura T; Urano T; Takahashi S; Inoue S
    Oncogene; 2017 Nov; 36(45):6272-6281. PubMed ID: 28692047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.
    Guo Y; Cui J; Ji Z; Cheng C; Zhang K; Zhang C; Chu M; Zhao Q; Yu Z; Zhang Y; Fang YX; Gao WQ; Zhu HH
    Oncogene; 2017 Nov; 36(45):6336-6347. PubMed ID: 28745315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
    Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
    Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.
    Song S; Honjo S; Jin J; Chang SS; Scott AW; Chen Q; Kalhor N; Correa AM; Hofstetter WL; Albarracin CT; Wu TT; Johnson RL; Hung MC; Ajani JA
    Clin Cancer Res; 2015 Jun; 21(11):2580-90. PubMed ID: 25739674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
    Ramamurthy VP; Ramalingam S; Gediya LK; Njar VCO
    FEBS J; 2018 Mar; 285(6):1051-1063. PubMed ID: 29323792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis.
    Zhou Y; Zhang J; Li H; Huang T; Wong CC; Wu F; Wu M; Weng N; Liu L; Cheng ASL; Yu J; Wong N; Lo KW; Tang PMK; Kang W; To KF
    Oncogene; 2020 May; 39(22):4375-4389. PubMed ID: 32313226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 35. 20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.
    Cao B; Qi Y; Yang Y; Liu X; Xu D; Guo W; Zhan Y; Xiong Z; Zhang A; Wang AR; Fu X; Zhang H; Zhao L; Gu J; Dong Y
    PLoS One; 2014; 9(11):e111201. PubMed ID: 25375370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The activation of OR51E1 causes growth suppression of human prostate cancer cells.
    Maßberg D; Jovancevic N; Offermann A; Simon A; Baniahmad A; Perner S; Pungsrinont T; Luko K; Philippou S; Ubrig B; Heiland M; Weber L; Altmüller J; Becker C; Gisselmann G; Gelis L; Hatt H
    Oncotarget; 2016 Jul; 7(30):48231-48249. PubMed ID: 27374083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FFAR1-and FFAR4-dependent activation of Hippo pathway mediates DHA-induced apoptosis of androgen-independent prostate cancer cells.
    Wang J; Hong Y; Shao S; Zhang K; Hong W
    Biochem Biophys Res Commun; 2018 Nov; 506(3):590-596. PubMed ID: 30366669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.
    Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
    Cancer Lett; 2018 Jun; 423():36-46. PubMed ID: 29452146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
    Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
    J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
    Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
    Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.